Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MH-001 in healthy participants
NCT06780254Phase 1Completed
- Sponsor
- Vespina Lifesciences
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing MH-001 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 28 days. Started Sep 2024; status: completed.
02
Drugs
MH-001
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06780254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780254.